Paronychia is a painful inflammatory disorder of the nail fold. Periungual pyogenic granuloma -a benign vascular tumor of the capillaries -can develop as a complication of paronychia. We report both, paronychia and periungual pyogenic granuloma, as possible adverse events during systemic drug-therapy. The following groups of systemic drugs have been considered: taxanes, epidermal growth factor-receptor (EGFR) inhibitors, EGFR tyrosine kinase inhibitors, tyrosine kinase inhibitors, inhibitors of MEK/ERK, BRAF inhibitors, CD20 antagonists, vascular endothelial growth factor inhibitors, and retinoids. Recommendations for prevention and treatment are given. Since paronychia is a painful inflammatory disorder that has a negative impact on daily activities, early recognition and adequate treatment improve adhesion to treatment and quality of life.
Introduction
Paronychia is defined as an inflammation of the nail folds of fingers or toes. Paronychia can occur as an acute or chronic disease. Commonly, acute paronychia is a consequence of impaired protective function of skin and caused by bacterial infections. Other etiologies are viruses, fungi, pemphigus vulgaris, or trauma (finger sucking). [1] Paronychia is considered to be chronic if symptoms of at least 6 weeks duration are reported. In many cases, chronic paronychia is caused by an irritant contact dermatitis [ Figure 1 ]. [2] Pyogenic granuloma (PG), also called lobular capillary hemangioma and teleangiectatic granuloma, is a benign vascular proliferation of skin and mucous membranes that develops after minor trauma [ Figure 2 ]. PG can be a consequence of chronic paronychia. Bleeding and secondary infections are possible complications. [3] In this review, we will focus on paronychia and PG caused by systemic drugs. Although the onset of the disease may be acute, the course often becomes chronic due to the need to continue the systemic drug treatment.
Taxanes
Taxanes such as docetaxel and paclitaxel are anticancer drugs approved for the treatment of metastatic or locally advanced breast, nonsmall cell lung cancer (NSCLC), prostate, gastric, head-and-neck, and ovarian cancers. These drugs inhibit cancer cell proliferation by supporting the polymerization of tubulin into highly stable intracellular microtubules. Nail changes have been reported in 40-89% during treatments with onycholysis and discoloration as the most common findings. Paronychia is an uncommon adverse event. [4, 5] 
Epidermal Growth Factor-receptor Inhibitors
Epidermal growth factor-receptor inhibitors (EGFRI) are drugs targeting the extracellular domain of the epidermal growth factor receptor. Cetuximab which is a recombinant IG1 mouse-human chimeric anti-EGFR monoclonal antibody, and panitumumab, is a recombinant, fully human IG2 anti-EGFR monoclonal antibody.
Cetuximab was approved for metastatic colorectal cancer and advanced head-and-neck squamous cell carcinoma.
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This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. There is also some evidence that cetuximab has efficacy on other types of nonmelanoma skin cancer as well. [6] Paronychia is one of the most common cutaneous adverse event during treatment with cetuximab seen in approximately 10% of the patients. [7, 8] Panitumumab was approved as a first-line monotherapy for the treatment of patients with metastatic colorectal cancer and confirmed wild-type KRAS tumor. [9] Epidermal growth factor-receptor tyrosine kinase inhibitors Gefitinib [N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy) quinazolin-4-amine] inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme (EGFR-TKI). Thereby, the function of the EGFR tyrosine kinase in activating anti-apoptotic Ras signal transduction cascade is inhibited. Gefitinib is used to treat NSCLC, esophageal cancer and breast cancer among other malignancies. [10] Paronychia occurs in about two-third of cancer patients treated with gefitinib. [11] Paronychia has been reported in 13% to 22% of patients as adverse event. [9] Although associated with handicap for hand grip and fine motors skills, paronychia usually does not warrant treatment interruption or cessation [ Figure 3 ].
Erlotinib [N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy) 4-quinazolinamine] is an EGFR-TKI that competes with adenosine triphosphate for binding with the intracellular catalytic domain of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase, thereby inhibiting receptor phosphorylation. After receptor binding, the downstream signal transduction is blocked and the tumorigenic effects associated with ligand-dependent and ligand-independent HER1/EGFR activation become inhibited. This drug has been approved for NSCLC and pancreatic cancer. [12] Erlotinib causes paronychia in approximately 28-40% of NSCLC patients. [13, 14] Another selective reversible EGFR-TKI is icotinib [4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4quinazoline]. [15] Trials have investigated anti-tumor activity and safety in NSCLC. [16] It has been assumed that the shorter half-life of icotinib compared to the two other first-generation EGFRI's is responsible for a reduced percentage of acneiform rash and diarrhea. Detailed data on nail affection by icotinib have not been identified in English literature, but from the basic principle of action, paronchia is a possible adverse event. [17] Afatinib
oxyquinazolin-6-yl]-4-(dimethylamino) but-2-enamide] is a second-generation EGFR-TKI. It inhibits ErbB signaling by covalently binding to the kinase domains of EGFR, human epidermal growth factor receptor (HER)2, and HER4. This results in an irreversible inhibition of tyrosine kinase autophosphorylation. Afatinib also prevents transphosphorylation of HER3. [18] The drug has been approved for NSCLC but trials have shown anti-tumor activity also in advanced head-and-neck squamous cell carcinoma and urothelial carcinoma. [19, 20] Osimertinib is a third-generation irreversible EGFR-TKI showing inhibitory activity on EGFR T790M substitution mutation but less affinity for wild-type EGFR. This could be responsible for minimizing the cutaneous and gastrointestinal toxicities associated with first-and second-generation EGFR-TKI therapy. [21] The drug has been approved for advanced NSCLC. Paronychia has Figure 4 ]. [22, 23] 
Tryosine Kinase Inhibitors
Tyrosine kinase inhibitors (TKIs) target protein tyrosine kinases (PTKs), which exist as transmembrane receptors or as intracellular nonreceptor PTKI. The TKIs are widely used clinically for the treatment of such malignancies as chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and renal cell carcinoma. [24] Imatinib blocks nonreceptor Abelson tyrosine kinase and several other targets. Imatinib-induced periungual PG has been observed occasionally. [25] 
MEK-and ERK-inhibitors
The Ras-Raf-mitogen-activated protein kinase (MAPK) cascade is a central effector of cellular differentiation in development and the inappropriate and continuous activation provides a potent promitogenic force and is a very common occurrence in human cancers. MEK-and ERK-inhibitors (MEKI/ERKIs) have been developed and approved for a variety of malignancies including metastatic melanoma. [26] Cometinib is a potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor approved for combination with vemurafenib in metastatic melanoma. [27] Trametinib is another selective MEK1/2 inhibitor for combined treatment with sorafenib in stage IV melanoma. [28] For both combinations, no significant development of paronychia has been observed.
Selumetinib
is a second-generation MEKI. Selumetinib-induced paronychia is characterized by a delayed onset, erythema, swelling, ingrown nail, and resolution upon treatment interruption. The percentage of this adverse event was 9% in one study. [29] 
BRAF Inhibitors
Rapidly accelerated fibrosarcoma (RAF), a proto-oncogene product, and BRAF are members of the RAF kinase family. BRAF and RAF are activated by RAS (rat sarcoma). RAF proteins are growth signal transduction protein kinases and their signaling cascade induces gene expression which alters mutagenesis and may also potentiate oncogenesis. [30] BRAF inhibitors (BRAFI) are approved for advanced cancers including cutaneous melanoma. [31] Vemurafenib is first-in-class small molecule inhibiting of V600 mutant BRAF. [32] Dabrafenib is another potent and selective BRAF inhibitor with clinical activity against BRAFV600E melanoma, non-BRAFV600E-mutated melanoma, and cancers of other organ systems with the V600K mutation. [33] Sorafenib is a V600E mutant BRAF and CRAF tyrosine kinase inhibitor with specificity for the ATP-binding pocket of RAF. It also targets the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Sorafenib has been shown to disable the BRAF kinase domain by locking the enzyme in its inactive form and inhibiting the MEK pathway in vitro and in vivo. [34] Vemurafenib is known to induce paronychia but trials suggest that this adverse effect is uncommon. [31, 35] 
Anti-CD20 monoclonal antibody
Rituximab is a chimeric murine/human monoclonal antibody that binds to CD20 on benign and malignant B-lymphocytes leading to a rapid cell depletion. The drug is widely used in hemato-oncology, rheumatology, and dermatology. [36] Multiple periungual PG's have been observed in a 73-year-old female patient suffering from rheumatoid arthritis treated by rituximab [ Figure 5 ]. [37] 
Vascular endothelial growth factor-inhibitors
The vascular endothelial growth factor (VEGF) signaling pathway plays a dominant role in stimulating tumor angiogenesis. VEGF is overexpressed by most solid tumors and increased levels of VEGEF have also been measured in the circulation of tumor patients. [38] Bevacizumab is a recombinant, humanized IgG1 monoclonal antibody that blocks VEGF. It has been used successfully in combined treatments of NSCLC, breast cancer, renal carcinoma, and glioblastomas. It is also used intravitreally to combat macular degeneration. [39] Ranibizumab is a recombinant humanized monoclonal antibody fragment that particularly binds VEGF-A including its cleaved isoform VEGF110. The indication for this compound is macular degeneration. The application is intravitreal.
Adverse events affecting the nail have been reported for bevacizumab but not ranibizumab, what is probably related to dosage and application. [40] However, intravitreal injection of VEGFI can induce PG of the conjunctiva. [41, 42] We observed chronic paronychia in a patient with colorectal cancer treated with bevacizumab-FOLFIRI (5-fluorouracil, folinic acid, irinotecan) [ Figure 6 ].
Retinoids
Isotretinoin is an FDA-approved drug for nodulocystic acne. In a large series of acne patients, chronic paronychia and hypergranulation of the lateral nail folds have been described in four patients. [43, 44] Such adverse events are more often seen with etretinate and less with acitretin. [45] In rare cases, PG formation has been observed in patients treated with acitretin. [46, 47] 
Prevention and Treatment
Patients selected for any of the abovementioned systemic drug therapies should be informed of possible adverse effects to the nail apparatus including paronychia. They should be educated about appropriate nail care (manicure, pedicure) and the regular use of skin barrier creams to protect the nail folds before and during treatment. It is very important to avoid traumatization of the nail structure. [48] For mild cases, topical solution comprised 2% povidone-iodine in a dimethylsulfoxide vehicle has been shown to be effective in 76% of nails affected within 6 weeks of treatment. [49] The combination of corticosteroid and topical fusidinic acid seems to be superior to topical antibiotics alone. [50] On chronic paronychia, PG can develop easily. In such patients, surgery or laser-surgery is a treatment option to reduce the time to complete healing. [3] 
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